Factor Xa inhibition by rivaroxaban attenuates cardiac remodeling due to intermittent hypoxia.

Imano, Hideki

Factor Xa inhibition by rivaroxaban attenuates cardiac remodeling due to intermittent hypoxia. [electronic resource] - Journal of pharmacological sciences Jul 2018 - 274-282 p. digital

Publication Type: Journal Article

1347-8648

10.1016/j.jphs.2018.07.002 doi


Animals
Atrial Fibrillation--etiology
Cells, Cultured
Endothelial Cells--pathology
Factor Xa Inhibitors--pharmacology
Fibrosis--prevention & control
Hypoxia--complications
MAP Kinase Signaling System--drug effects
Male
Mice, Inbred C57BL
Molecular Targeted Therapy
Myocardium--pathology
NF-kappa B--metabolism
Oligopeptides--pharmacology
Oxidative Stress--drug effects
Receptor, PAR-2--antagonists & inhibitors
Rivaroxaban--pharmacology
Sleep Apnea, Obstructive--complications
Ventricular Remodeling--drug effects